CDKN2A and central nervous system cancer: This study performs semi-quantitative analysis for p16 expression across 100 IDH-wildtype and IDH-mutant gliomas, using three independent p16 immunoreactivity scores, and correlates the extent of p16 expression with CDKN2A homozygous deletion as determined by next-generation DNA sequencing.